Intermediate-to-High-Risk Mantle Cell Lymphoma
1 clinical trials · Condition
◉ Watch Intermediate-to-High-Risk Mantle Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL (NCT07548255) | Ruijin Hospital | 2026-04-20 |
Track Intermediate-to-High-Risk Mantle Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.